Checchi Capital Advisers LLC cut its holdings in Pfizer, Inc. (NYSE:PFE) by 7.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 66,312 shares of the biopharmaceutical company’s stock after selling 5,477 shares during the period. Checchi Capital Advisers LLC’s holdings in Pfizer were worth $2,227,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in PFE. Alexandria Capital LLC lifted its holdings in Pfizer by 3.5% in the 1st quarter. Alexandria Capital LLC now owns 7,153 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 245 shares in the last quarter. Glen Harbor Capital Management LLC lifted its holdings in Pfizer by 41.9% in the 1st quarter. Glen Harbor Capital Management LLC now owns 134,304 shares of the biopharmaceutical company’s stock valued at $4,595,000 after purchasing an additional 39,632 shares in the last quarter. Cubic Asset Management LLC lifted its holdings in Pfizer by 0.8% in the 1st quarter. Cubic Asset Management LLC now owns 174,267 shares of the biopharmaceutical company’s stock valued at $5,962,000 after purchasing an additional 1,380 shares in the last quarter. Dubuque Bank & Trust Co. lifted its holdings in Pfizer by 2.1% in the 1st quarter. Dubuque Bank & Trust Co. now owns 38,005 shares of the biopharmaceutical company’s stock valued at $1,300,000 after purchasing an additional 768 shares in the last quarter. Finally, Delta Asset Management LLC TN lifted its holdings in Pfizer by 1.7% in the 1st quarter. Delta Asset Management LLC TN now owns 44,949 shares of the biopharmaceutical company’s stock valued at $1,538,000 after purchasing an additional 769 shares in the last quarter. Institutional investors and hedge funds own 69.36% of the company’s stock.

In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the sale, the insider now owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. Insiders sold 374,621 shares of company stock valued at $12,796,098 in the last ninety days. 0.06% of the stock is owned by corporate insiders.

PFE has been the topic of a number of recent research reports. BMO Capital Markets restated a “buy” rating and issued a $37.00 target price on shares of Pfizer in a report on Wednesday, September 6th. Vetr lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price on the stock. in a report on Wednesday, September 13th. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Tuesday, October 3rd. Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $35.00 to $39.00 in a report on Wednesday, September 20th. Finally, ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $38.48.

Shares of Pfizer, Inc. (PFE) opened at $35.37 on Friday. The stock has a market cap of $211,960.00, a P/E ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a 1 year low of $30.51 and a 1 year high of $36.78. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company’s revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.61 EPS. analysts expect that Pfizer, Inc. will post 2.6 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.62%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is 78.53%.

WARNING: This article was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/11/19/checchi-capital-advisers-llc-sells-5477-shares-of-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.